PHS
SPRB

PFM Health Sciences’s Spruce Biosciences SPRB Stock Holding History

PFM Health Sciences’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,528
Closed -$8.13M – 101
2021
Q1 		$8.13M Sell
6,528
-529
-7% -$812K 0.25% 72
2020
Q4 		$12.9M Buy
+7,057
New +$11.7M 0.45% 67

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

PFM Health Sciences's SPRB Position: Q2 2021 in Review

PFM Health Sciences sold out of Spruce Biosciences (SPRB) in Q2 2021, closing a stake of 6,528 shares — an estimated $8.13M sold.

PFM Health Sciences first reported a position in SPRB in Q4 2020 and held it in 2 quarters. The position peaked at $12.9M in Q4 2020. 41 funds tracked by Wall St. Rank hold SPRB as of Q2 2021.

  • PFM Health Sciences reported no remaining Spruce Biosciences position as of Q2 2021 after selling out during the quarter.
  • PFM Health Sciences sold 6,528 Spruce Biosciences shares in Q2 2021, an estimated $8.13M.
  • PFM Health Sciences first reported a position in Spruce Biosciences in Q4 2020 and held it in 2 quarters.
  • PFM Health Sciences's Spruce Biosciences position peaked at $12.9M in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2021.

Based on PFM Health Sciences's 13F filing for Q2 2021, filed 16 Aug 2021.